{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"111.0","upperLimit":"130.0","value":"120.5"},{"groupId":"OG001","lowerLimit":"85.0","upperLimit":"225.0","value":"112.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Duration of time from the date of start of study treatment to the date of disease progression. Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Assigned to 60 mg, 6 doses/cycle","id":"OG000","title":"Selinexor (PTCL)"},{"description":"Assigned to 60 mg, 6 doses/cycle","id":"OG001","title":"Selinexor (CTCL)"}],"paramType":"MEDIAN","populationDescription":"Those participants with stable disease, including those with partial response, as a subset of the Intent to Treat (ITT) population","reportingStatus":"POSTED","timeFrame":"Date of start of study treatment to date of progression. Patients without documented PD are censored on date of last radiologic assessment.","title":"Duration of Stable Disease, Including Patients With Partial Response","type":"SECONDARY","unitOfMeasure":"Days"}